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In a 60 month period (January 1981 to December 1985),
82 patients (79% male with a mean age of 60 years) had
83 saphenous vein grafts and 5 internal mammary artery
grafts with a total of 101 stenotic sites treated with per-
cutaneous transluminal coronary angioplasty. The mean
time between bypass surgery and angioplasty was 51.2
months. The procedure was technically successful in 85%
of patients, 86% of grafts and 85% of the sites at-
tempted. In these cases, the mean diameter stenosis was
reduced from 77 ± 14 to 27 ± 20% (p < 0.001), the
mean pressure gradient from 49 ± 16 to 7 ± 6 mm Hg
(p < 0.001). Emergency coronary artery bypass graft
surgery was necessary in one patient (1.2%) whereas
myocardial infarction occurred in three patients (3.6%).
There were no hospital deaths.
Clinical follow-up was obtained in all 82 patients.
Before angioplasty, 23% were in Canadian Cardiovas-
cular Society functional class II, 60% in class III and
17% in class IV. With a mean clinical follow-up period
of 21.4 ± 2.3 months, 71% are in class I, 17% in class
Since the introduction of direct internal mammary-coronary
artery anastomosis by Kolessov (I) in 1967 and use of
saphenous vein-coronary artery grafts by Favaloro (2) in
1968, these conduits have been widely utilized in the treat-
ment of ischemic heart disease. Long-term follow-up of
patients with saphenous vein grafts has revealed a high
incidence of recurrence. Angiographic studies (3-7) have
shown occlusive disease at the anastomotic site or in the
graft itself in over one-third of patients in the 10 years after
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II and 12% in class III. There were two deaths, 3 months
or more after angioplasty, one probably due to graft
closure. So far, angiographic follow-up (at 7.9 ± 2.1
months) has been available in 26 patients. Ten patients
(with 10 grafts) exhibited graft restenosis; six of them
have had second successful repeat angioplasty. Among
the many variables analyzed, statistically significant pre-
dictors of success were a higher measured balloon/graft
ratio (p < 0.001), smaller diameter graft (p < 0.001),
and shorter lesion length (p < 0.01). The only predictor
of complication was diffuseness of disease in the graft
(p < 0.05). The statistically significant predictors of re-
currence were the residual stenosis after the initial an-
gioplasty (p < 0.01) and the measured balloon/graft ratio
(p < 0.01).
Angioplasty of coronary artery grafts appears to be
a feasible and efficacious procedure with a low compli-
cation rate. The technique is a satisfactory alternative
to repeat surgery in selected patients.
(J Am Coil Cardiol1987;9:8-17)
surgery. In the nearly 2 decades since coronary bypass sur-
gery has been in clinical use, more patients are now being
reevaluated for symptomatic ischemic heart disease after
revascularization surgery. Until recently, the approach to
the treatment of this subset of patients has been either med-
ical therapy or a repeat surgical revascularization procedure,
the latter in patients in whom adequate symptomatic control
could not be achieved. However, performing a second (or
third) operation is not without serious implications. Being
technically more difficult, the revascularization is frequently
incomplete, and there are higher morbidity and mortality
rates (8-12).
Gruentzig et al. (13-16) and Stertzer et al. (17) were the
first to report the use of an angioplasty balloon catheter in
the treatment of coronary atherosclerotic disease in humans.
Since 1977, because of significant technological improve-
ment and greater experience, the original indications have
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widened considerably (18 ,19) , The use of this procedure
has become safer as well as more successful.
This report summarizes our experience using angioplasty
as the revascularization technique for stenotic saphenous
vein and internal mammary grafts in patients with angina
relatively refractory to medical management.
Methods
Data acquisition. All cases of percutaneous translu-
minal angioplasty of saphenous vein and internal mammary
artery bypass grafts performed at the San Francisco Heart
Institute between January 1981 and December 1985 inclu-
sive (60 months) were retrospectively reviewed, The clinical
information was obtained by consulting the medical record
files as well as by contacting the patients or their referring
physicians, or both. The details of each procedure were
collected by review of the catheterization laboratory pro-
tocols . Angiographic data were obtained from the coronary
arteriograms before and after dilation, and at follow-up when
available ,
Two ratios were generated from the angiographic data.
The " measured balloon/graft" ratio was defined as the mea-
surement of the inflated balloon diameter at maximal infla-
tion pressure (at the site of the lesion). The largest mea-
surement in the various projections was used. A second
ratio, which will be called "expected balloon/graft" ratio ,
was derived from the commercially listed balloon size and
the measured graft diameter.
All of the dilation catheters used in this study were from
USCI (United States Catheter and Instrument Co., Inc.) .
The balloons in all cases but one were of polyvinyl chloride,
a product with known compliance characteristics at various
inflation pressures (that is, balloon diameters are larger at
higher inflation pressures) (20,21), Measurements were per-
formed using electronic calipers and a computer-assisted
system (A2D Protocol 110 I, Programmable Digital Caliper,
Hewlett-Packard, Inc.) , calibrating to zero and to the di-
ameter of the angioplasty guiding catheter (8F == 2 .67 mm) .
Pre- and postangioplasty percent diameter stenosis and le-
sion length were measured in three angiographic views, the
computer calculating the mean of these results.
The graf ts were divided into five anatomical sites: the
proximal anastomosis (Fig. I), the proximal, mid and distal
third of the graft shaft and the distal anastomosis (Fig. 2
and 3) . The distribution of the lesions at these various sites
is displayed in Table I .
Clinical patient profiles. Bypass graft angioplasty was
attempted in 82 patients. 65 male and 17 female , with an
age range of 38 to 78 years (mean 59.7) . A total of 83
saphenous vein grafts and 5 internal mammary artery grafts
with 10I stenotic sites were dilated . Sixty-eight patients
underwent angioplasty at one site, nine at two sites and five
at three sites. The right coronary artery was the insertion
site for 18 of the "target" saphenous vein grafts, the left
circumflex for 21 saphenous vein graft s and the left anterior
descending artery for 49 grafts (42 saphenous vein, 5 in-
ternal mammary artery and 2 Sewell graft s). All the patients
had disabling angina relatively refractory to medical therapy
and an abnormal treadmill stress test if they were able to
exercise. Symptomatic status was classified according to the
Canadian Cardiovascular Society Functional Classification
criteria (22) ; 23% were in class II, 60% in class III and 17%
in class IV before angioplasty . Insulin-dependent diabetes
mellitus was found in 21% of patients, elevated serum tri-
glycerides in 35% and elevated serum cholesterol in 22%.
Sixty-five percent of patients were smokers at the time of
angioplasty. The mean period since bypass surgery was
51. 2 ± 40 months (range 2 to 144); of the 82 patients. 50
(61%) had had their bypass surgery 12 months or more
before coronary angioplasty , The mean duration of symp-
toms at the time of the procedure was 6 .7 ± 9 months
(range I to 60) .
All patients were maintained on their original medical
therapy until the angioplasty . Twelve to 24 hours before the
procedure. they were started On a regimen of aspirin (325
mg daily) and dipyridamole (50 to 75 mg orally) three times
a day. All patients were given a premedication regimen
including secobarbital sodium and a calcium channel blocker
(usually nifedipine, 10 mg orally). A bolus of 10,000 units
of heparin was administered after the cannulation of the
entrance artery (femoral or brachial) and supplemented as
needed based on the duration of the angioplasty .
AngiopIasty technique. All the angioplasty procedures
were performed by one of three experienced physicians uti-
lizing the femoral (52 grafts) or brachial (32 grafts) tech-
niques, or both (4 grafts), as described elsewhere (19,23) .
Various femoral guiding catheters were used to achieve the
most stable position in the orifice of the graft (19). The
most commonly used femoral guiding catheters were a right
Judkins or left venous bypass style for saphenous vein-left
anterior descending and saphenous vein-left circumflex grafts,
and a right venous bypass. multipurpose (King) , Stertzer
femoral or Arani style for the saphenous vein-right coronary
artery graft. Guiding catheter selection was determined by
the configuration and orientation of the saphenous vein graft
and the diameter of the ascending aorta (19). All five internal
mammary artery graft lesions involved the distal anasto-
mosis of the left internal mammary and the left anterior
descending artery. Four of these procedures were performed
using an internal mammary artery guiding catheter from the
femoral approach and one by way of the left brachial artery
employing a Stertzer brachial guiding catheter.
The size of the balloon catheter was selected to match
as closely as possible the diameter of the saphenous vein
graft or the internal mammary artery graft when dilating the
proximal anastomosis and graft shaft lesions. The diameter
of the native vessel was the determinant of balloon size for
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distal anastomotic lesions. The dilation catheter balloons
were inflated to achieve as full expansion as possible within
the pressure limits of the balloon. The duration of inflation
was determined by the longest inflation period tolerated
without signs of severe ischemia. Multiple inflations were
performed to obtain optimal angiographic results and to
reduce the transstenotic pressure gradient to less than 15
mm Hg. The pressure gradient across the lesions before and
after angioplasty was obtained with a dilation catheter sys-
tem utilizing standard pressure transducers.
After successful balloon angioplasty, the patients were
Figure1. Coronary angiograms. A and B, Left lateral projection
of saphenous vein graft to left anterior descending coronary artery
showing severe stenosis (arrow) at the proximal anastomosis (A)
before and (B) after angioplasty. Note attenuation of filling of the
left anterior descending artery before angioplasty. C and D, Left
lateral projection showing balloon inflated on lesion (C) at 15 atm
(15A) showing indentation (arrow) and (D) 19 atm (l9A) showing
full expansion of balloon (PE PLUS balloon, USCI).
monitored for 24 hours and, if stable, were discharged on
aspirin and dipyridamole. They were kept on this regimen
for at least 6 months. In two cases involving total occlusion
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Technical aspects. The mean maximal inflation pressure
was 9.5 :±: 2.2 atmospheres (range 5 to 19) with a mean
maximal inflation time of 52 :±: 18 seconds (range 25 to
Figure 3 . Coronary angiograms. Left lateral projection of in-
ternal mamm ary artery graft to the left anteri or descending artery
with severe stenos is (ar row) at distal anastomosis (A) before and
(B) after angioplasty.
...
a
A
Figure 2. Coronary angiograms . Left anteri or oblique projection
of sequential saphenous vein graft to diagonal and left anterior
descending arteries showing mid-graft stenosi s (closed arrow) and
a second stenosis (open arrow) at the distal anastomotic site (A)
before and (B) after angioplasty . Note attenuation of flow into the
left anteri or descending artery before angioplasty.
of the saphenous vein graft, the patient s were discharged
on warfarin instead of aspirin . In addition , nitrates (oral or
topical) and a calcium channel blocker (nifedipine, 10 mg
four times a day) were used for at least 3 months after
angioplasty . Clinical follow-up was obtained in all the cases.
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Table 1. Saphenous Vein/Internal Mammary Artery Graft Angioplasty: Distribution of
Anatomic Sites, Follow-up and Recurrence of Stenosis
Initially Follow-Up Recurrence
Site No. % No. %* No. %t
Proximal anastomosis 14 14 9 64 3 33
Shaft
Proximal third 16 16 10 63 2 20
Middle third 22 22 7 32 2 29
Distal third 6 6 4 67 I 25
Distal anastomosis 43 42 13 30 2 15
Total 101 100 43 42 10 23
*Percent of initial sites restudied angiographically (for example, 9 of 14 = 64%); tpercent of restudied
sites (for example, 3 of 9 = 33%).
JACC Vol. 9, No. I
January 1987:8-17
120). An average of 4 ± 2 inflations (range 1 to 9) were
performed per patient. The mean percent diameter stenosis
before angioplasty was reduced from 77 ± 14 to 27 ±
20% (p < 0.001), the mean pressure gradient from 49 ±
16 to 7 ± 6 mm Hg (p < 0.001). The mean lesion length
was 5.7 ± 4 mm and the average graft diameter was
3.4 ± 0.7 mm (range 2.2 to 5.0). The mean diameter of
the native vessels distal to the anastomosis of the graft was
2.4 ± 0.4 mm (range 1.5 to 4.5). Recently, baseline and
hyperemic coronary flow reserve using digital subtraction
angiography and color mapping techniques have been
performed before and after angioplasty (24).
Results
Initial findings. Technical success was defined as re-
duction in the initial percent diameter stenosis of 35% or
more and reduction in the transstenotic pressure gradient to
15 mm Hg or less with no complications requiring coronary
artery bypass surgery or resulting in myocardial infarction.
In 70 (85%) of the 82 patients all graft and lesion sites were
successfully dilated; in 76 (86%) of the 88 grafts all sites
were successfully dilated; and in 86 (85%) of the 101 sites
technical success was achieved. In all five internal mammary
artery-left anterior descending artery grafts, the distal anas-
tomotic site stenosis had successful angioplasty. There were
12 unsuccessful or complicated cases: a) three patients had
complications, two with distal embolization, one with total
occlusion; b) in six patients there was failure to cross the
stenosis; c) in the other three cases, although inflation of
the balloon to the maximal pressure limits was achieved,
there was insignificant change in the stenosis after angio-
plasty. These latter three cases were performed before the
availability of the "high pressure" balloon and in these
instances the measured balloon/graft ratio was below 0.811.0.
Despite the use of relatively high pressure (mean =
9.5 ± 2.2 atm) during inflation, many balloons were not
fully expanded when measured at peak pressure. These were
all standard pressure « 10 atm) balloon catheters. In one
instance, a high pressure balloon catheter was available, and
was inflated to 19 atm. The balloon was still indented at 15
atm (Fig. lC) but fully expanded at 19 atm (Fig. lD).
Definition and predictors of success. Clinical success
was defined as technical success in all the grafts and lesions,
no complications requiring emergency coronary artery by-
pass surgery or resulting in myocardial infarction and an
improvement in at least one functional anginal class (and
improvement in exercise testing with nuclear scintigraphy
if available). In this series of 82 patients, 70 had a tech-
nically and clinically successful angioplasty in all grafts and
stenotic sites. In the 12 unsuccessful cases, the patients were
treated medically or with repeat coronary artery bypass sur-
gery.
Patient age and sex, anginal class and duration, diabetes,
hypercholesterolemia, smoking history, graft age, native
vessel grafted, native vessel diameter, lesion site in graft
and percent diameter stenosis and pressure gradient before
and after angioplasty were not statistically significant pre-
dictors of success. By univariate partial correlation analysis
controlling for the percent diameter stenosis before angio-
plasty, predictors of angiographic (technical) success in-
cluded a higher measured balloon/graft ratio (p < 0.001),
higher expected balloon/graft ratio (p < 0.001), smaller
graft diameter (p < 0.001) and shorter lesion length (p <
0.01). Using multiple regression analysis, the measured and
expected balloon graft ratios (both p < 0.01) were the only
predictors of success. A measured ratio over 1.1: 1.0 was
associated with the lowest residual percent diameter stenosis
after angioplasty (Fig. 4).
Complications. Three patients (3.6%) had either distal
coronary embolization (two) or abrupt closure (one) after
angioplasty resulting in evidence of myocardial infarction
(new Q waves in the electrocardiogram and creatine kinase-
myocardial brain fraction of 6% or more). One of these
patients (1.2%) underwent emergency coronary artery by-
pass surgery with embolic debris flushed from the native
vessel at the time of surgery (Fig. 5). No hospital deaths
occurred in this series. The incidence of major cardiac events
(myocardial infarction, emergency coronary artery bypass
surgery or death) was 3.6%. In addition, two patients had
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in at least one site. The patients with patent grafts had
normalization (or significant improvement) in exercise
(treadmill) testing and no evidence of reversible ischemi a
by nuclear scintigraphy. In the 10 patient s with recurrence,
7 had no change in clinical classification and had exerci se
Figure 5. A. Angiogram (right anterior oblique [30°1 projection)
of saphenous vein graft to the right coro nary artery showing nu-
merous stenotic lesions (a r rows) before attempted angioplasty.
Immediately after angioplasty, there was evidence of evolving
inferior myocardial infarction and the patient was taken for emer-
gency surgery. Emboli c debris was flushed from the distal native
right coro nary artery. A new saphenous vein graft was placed. B,
The old saphenous vein graft was removed and showed evidence
of friable atheromatous mater ial and old and recent thrombus.
Figure 4. Relation of average percent diameter stenosis (PDS)
after angioplasty (PTCA) versus balloon/graft ratio.
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a minor complication: one had transient heart block and the
other an episode of ventricular tachycardia that responded
to an intravenous bolus injection of lidocaine .
Patient age. sex . anginal class and duration . diabetes
mellitus. hypercholesterolemi a. smoking history, graft age,
graft or native vessel diameter. balloon size, native vessel
grafted, site of lesion in graft, percent diameter stenosis or
pressure gradient before and after angioplasty were not sta-
tistically significant predictors of procedural complications.
By univariate analysis, the only significant predictor of com-
plications was the presence of diffuse atheromatous disease
in the grafts (p < 0.05). These grafts were all surgically
placed 4 years or more before angioplasty.
Follow-up. Of the 70 patients in whom angiopl asty was
performed successfully, 26 so far have had angiographic
restudy at a mean of 7.9 ± 2. I months after angioplasty.
Of the remaining 44 patients, 21 have not yet passed their
6 month postangioplasty follow-up and therefore (by pro-
tocol) have not yet had repeat angiography. The remainin g
23 patients, who are more than 6 months postangioplasty.
have so far refused angiographic restudy because they are
clinically asymptomatic. have negative (normal) exercise
studies, or both . In our experience. postoperati ve patients.
unless symptomatic after angioplasty (or, for that matter.
after coronary bypass surgery) are more difficult to convince
to have repeat angiography. no doubt because they have
already had several prior invasive procedures.
In the 26 patients with postangioplasty angiographic doc-
umentation , all anatomic sites were represented in the fol-
low-up and there was no statistically significant difference
in their distribut ion (Table I). Restenosis was defined as a
decrease of 50% or more of the luminal diameter gain at
the time of angioplasty. Of these 26 patients , 16 had all
lesions patent and 10 had evidence of recurrence in at least
one site. In these 26 patients, 43 grafts had been dilated:
33 grafts were patent and 10 showed evidence of recurrenc e
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Figure 6. Average percent diameter stenosis after angiop1asty
versus patentgrafts and recurrent graft stenosis.
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100
testing abnormalities similar to their preangioplasty test re-
sults. The other three patients with recurrence had improve-
ment in their anginal class (class I or II) as well as exercise
testing results. These three patients had double graft (or
vessel) angioplasty with recurrence in only one graft; they
have been continued on medical therapy. Of the seven pa-
tients with angiographic recurrence and subjective and ob-
jective evidence of ischemia, six have had a second suc-
cessful angioplasty and one had uncomplicated elective repeat
coronary bypass surgery.
Predictors of graft restenosis at follow-up. The patient
age, sex, anginal class or duration, diabetes mellitus, hy-
percholesterolemia, hypertriglyceridemia, smoking history ,
graft age, graft diameter, native vessel grafted, percent di-
ameter stenosis before or pressure gradient before or after
angioplasty were not statistically significant predictors of
recurrence. Also, it was noteworthy that in our study the
site of stenosis in the graft was not a statistically significant
predictor of restenosis (Table I). When using a stepwise
multiple regression analysis, the percent diameter stenosis
immediately after dilation was a strong predictor of the
percent diameter stenosis at follow-up (p < 0.01). Using
the same analysis, the interaction of a high percent diameter
stenosis immediately after angioplasty and a low measured
balloon/graft ratio was also a strong predictor of restenosis
at follow-up. In further statistical analyses using restenosis
status as the outcome variable, there was a trend in which
higher percent diameter stenosis after angioplasty was re-
lated to higher incidence of recurrence (p = 0.07) (Fig. 6),
and lower "measured balloon/graft" ratio was significantly
related to higher incidence of recurrence (p < 0.01)
(Fig. 7).
Functional status and survival. In this series of 82
patients, with a mean clinical follow-up of 21.4 ± 2.3
months, 71% are in angina class I, 17% in class II and 12%
in class III. Eighty patients (97.6%) are alive at the present
time. There have been two late (more than 3 months after
--x =0.83 ± .09
5
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P -c .01
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•
8
3 _
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PATENT
.80
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angioplasty) deaths, one related to graft occlusion. Of the
82 patients, 66 have had angioplasty as their definitive pro-
cedure (including the 6 repeat angioplasties) for an overall
success (so far) of 80%.
Figure 7. Balloon/graft ratio versus graft patency and recurrent
graft stenosis.
1.00
1.20
L _
Discussion
Several years ago, many considered that the risk of per-
forming coronary angioplasty in postoperative patients was
prohibitive. There were higher morbidity and mortality rates
in the National Heart, Lung and Blood Institute PTCA
Registry (25,26) in patients who had previously undergone
coronary bypass surgery. In addition, there was a concern
that there would be distal coronary embolization in saphe-
nous vein graft angioplasty , and early results in this cohort
reported a high incidence of restenosis.
Initial success rate. In our series of coronary graft an-
gioplasty, we report a primary success rate of 85%. In
contrast to previous reports (27-29), the degree of residual
saphenous vein graft stenosis in our series was not influenced
by the location of the lesion in the graft. Structural changes
seen in the grafts (30-32) and used to support the variation
in the success rate at various sites (33) did not appear to
playa significant role in our patients. The difficulties in
fully distending the diseased segment of the graft, however,
was of primary importance. The only significant predictors
of immediate success by multivariate analysis were the mea-
sured and expected balloon/graft ratios. We believe that the
failure of the balloon to reach its expected diameter at the
site of the lesion would be best solved by the use of high
pressure balloons (for example, USCI PROFILE PLUS or
PE PLUS balloons which are made of polyethelene tere-
phthalate, a substance with high pressure tolerance and low
compliance). These balloons can achieve full inflation even
with "harder" atherosclerotic plaques (that is, those with
a higher percentage of fibrous and/or calcific material).RECURRED
•
•
--X=33.8±22
·
•
P = .07
•-~- x=22.1 ± 12
a
i
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Morbidity and mortality. The previously noted higher
complication rate of patients who were postoperative or had
graft angioplasty (25,26) has been countered by recent stud-
ies that showed a low incidence of morbidity (27,29,33-36).
Our series is comparable with other published data in that
regard, showing a major cardiac event incidence of 3.6%.
The low morbidity and mortality reported are most likely
related to technologic improvements (19) in the last few
years as well as to increasing experience of those physicians
who perform angioplasty. Incidentally, it is of interest to
compare this angioplasty data with the results from surgical
centers reporting morbidity and mortality in repeat coronary
bypass operations (8-11). In these centers, there were peri-
operative myocardial infarction incidences of 2 to 12% and
mortal ity rates of I to 17%.
Distal coronary embolization of an atheroma was re-
ported by Aueron and Gruentzig (37). In two of our patients,
both of whom had diffusely diseased grafts that were at least
4 years old, distal embolization was noted (one proved at
surgery). Therefore, we strongly urge avoiding angioplasty
in older grafts that show angiographic evidence of diffuse
disease (Fig. 5); if medical management cannot control the
angina in these patients with diffuse disease in old grafts,
then we recommend surgery rather than angioplasty as a
second line of therapy.
The needfor emergency bypass surgery occurred in only
one patient in our series. Yet, we firmly believe that emer-
gency revascularization surgery after unsuccessful graft an-
gioplasty represents a more significant challenge to the car-
diovascular surgical team. Surgeons with extensive experience
with myocardial revascularization and, in particular, emer-
gency surgery after unsuccessful angioplasty should be at
standby for these cases. It may be advisable to utilize an
intraaortic balloon pump in patients in whom abrupt reclo-
sure of a dilated graft occurs after angioplasty (38). This
may be especially important in patients who have had prior
cardiac surgery, because chest wall and pleuro-pericardial
fibrosis may delay reexposure of the heart during the second
(emergency) operation. The intraaortic balloon pump may
effectively stabilize the patient during this critical period.
Fortunately, this was only necessary in one of our patients.
Follow-up results: graft restenosis. Our clinical fol-
low-up results compare favorably with previously reported
saphenous vein graft angioplasty studies (34-36) and also
to reports of patients submitted to reoperation for coronary
artery disease (8-11). However, the true restenosis "rate"
in our series is not precisely known. Only 53% of the 49
successfully treated patients who have reached their 6 month
postangioplasty period have had follow-up angiography. Yet,
even if we use as the denominator only those patients who
have had angiographic documentation postangioplasty, our
recurrence rates were 38% for the 26 patients and 23% for
the 43 grafts. This would probably be the "worst case"
restenosis rate. On the other hand, it would not be fair to
state that we had a 14% (10 of the 70 successful cases)
restenosis rate, because 21 patients have not passed through
the 6 month "window of recurrence" (39,40). In addition,
23 patients who are more than 6 months postangioplasty
have so far refused restudy because they are asymptomatic
and have improved exercise studies. But "silent" recur-
rence has been reported in 5 to 14% of cases after angio-
plasty (39,41). Also, it should be noted that re-recurrence
will affect our restenosis incidence as well as the cost-
effectiveness of this technique compared with repeat coro-
nary bypass surgery (42).
Restenosis rates of 50% were reported by EI Gamal et
al. (36) and Reeder et al. (43). Dorros et al. (44) reported
50 and 53% recurrence rates at the proximal anastomotic
and graft shaft sites, respectively, and only 18% restenosis
rate at the distal anastomotic site. Douglas and coworkers
(28) noted the same discrepancy in restenosis rates, with
the lowest incidence occurring at the distal anastomotic site.
This site variation in recurrence was not corroborated in our
study (Table I). However, none of these studies, or, for
that matter, ours, had 100% follow-up angiographic doc-
umentation. Each recurrence site "cell" was small in these
series, as well as in ours, reducing the power of statistical
evaluation, making conclusions less reliable.
Nevertheless, one might implicate various pathologic
phenomena (30-32,35,45,46) at different sites in the graft.
Furthermore, Hollman (35) also noted a higher recurrence
rate (as well as acute embolic events) in older grafts. He
suggested that this may be related to changing graft disease
with age. Early changes in vein grafts are those of intimal
hyperplasia (47). In patients with normal lipids, unique ath-
erosclerotic changes develop after about 3 years (earlier in
hyperlipidemic patients) (45). Foam cells may erode through
the graft intima and the entire atheromatous plaque may be
more friable and more likely to embolize than those seen
in the native coronary arterial circulation.
Perhaps the higher residual stenosis after angioplasty re-
ported at the proximal anastomotic site (26,44) may explain
the higher recurrence rates previously noted. In our series,
however, there was no significant difference in postangio-
plasty percent diameter stenosis at the various sites in the
grafts. The measured balloon-graft ratios were the only sta-
tistically significant predictor of immediate (technical) suc-
cess and long-term results (Fig. 4 and 7).
Prior reports (28,34,44) as well as our data suggest that
a significant residual stenosis after angioplasty may affect
the long-term patency (Fig. 6). Higher postangioplasty re-
sidual stenoses may be due to atheroma that are "hard"
(high percentage of fibrous or calcific material) or due to
the use of a balloon that is too small relative to the graft
diameter. The use of high pressure balloons will certainly
permit more effective compaction of "hard" lesions. Fur-
thermore, it would appear that using balloons large enough
to achieve balloon/graft ratios of at least I. I : 1.0 may achieve
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more optimal initial technical results and, perhaps, increase
long-term patency. It should be emphasized, however, that
there may be an increased risk of dissection with indiscrim-
inate oversizing of balloons in relation to grafts or native
coronary arteries. Therefore, oversizing balloons should be
avoided with eccentric lesions on sharp curves in native
coronary arteries or grafts (48).
Finally, we suggest that because of problems associated
with identifying recurrence "rates" in series with less than
90% angiographic follow-up, "risk" of recurrence may be
a more meaningful concept. In this context, risk means the
likelihood, as predicted by certain factors, of recurrence of
stenosis in a particular patient (for example, patients with
lower balloon/graft ratio at baseline may be at higher risk
for recurrence). Therefore, risk refers to the cohort of pa-
tients who present for angiographic follow-up and is less
affected by the number of patients in the original sample.
Conclusions. Saphenous vein and internal mammary ar-
tery graft stenoses can be successfully treated with the coro-
nary angioplasty technique. An 85% initial success rate is
reported along with an emergency bypass incidence of 1.2%,
myocardial infarction incidence of 3.6% and major cardiac
event rate of 3.6%. No hospital deaths occurred. These
initial results compare favorably with similar angioplasty
studies and with the results of reoperation for saphenous
vein grafts stenosis. Careful selection of appropriate pa-
tients, avoiding those with diffusely diseased older grafts,
will further enhance the success rate and decrease the com-
plication rate. The problem of recurrence following native
coronary angioplasty has been described in detail elsewhere
(41,49-52), but graft angioplasty may offer particular in-
sights into this problem because of the different pathologic
processes in saphenous vein grafts. Higher pressure balloons
and efforts to achieve slightly larger balloon/graft ratios may
lead to a decrease in recurrence rates. Also certain phar-
macologic regimens may favorably affect the recurrence rate
after graft angioplasty (53,54).
With identification of those factors responsible for suc-
cess, complications and recurrence, coronary angioplasty
may well be the treatment of choice in symptomatic patients
with saphenous vein or internal mammary artery graft ste-
nosis.
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